Related references
Note: Only part of the references are listed.Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
New Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling Pathway
Gerhardt Attard et al.
CLINICAL CANCER RESEARCH (2011)
Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c
Fred Saad et al.
CLINICAL CANCER RESEARCH (2011)
Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)
C. Parker et al.
EUROPEAN JOURNAL OF CANCER (2011)
Drug resistance in metastatic castration-resistant prostate cancer
Bostjan Seruga et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Class III β-Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy
Guillaume Ploussard et al.
CANCER RESEARCH (2010)
Overcoming Persistent Dependency on Androgen Signaling after Progression to Castration-Resistant Prostate Cancer
Masuo Yamaoka et al.
CLINICAL CANCER RESEARCH (2010)
Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer
Kim N. Chi et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study
Howard I. Scher et al.
LANCET (2010)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
ABCG2: A potential marker of stem cells and novel target in stern cell and cancer therapy
Xi-wei Ding et al.
LIFE SCIENCES (2010)
Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?
Gerhardt Attard et al.
CANCER CELL (2009)
Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling
Liangli Zhao et al.
CANCER RESEARCH (2009)
ABCG2-mediated dyecycle violet efflux defined side population in benign and malignant prostate
Grinu Mathew et al.
CELL CYCLE (2009)
Change in Markers of Bone Metabolism with Chemotherapy for Advanced Prostate Cancer: Interleukin-6 Response Is a Potential Early Indicator of Response to Therapy
Kathleen M. Woods Ignatoski et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2009)
Ixabepilone: targeting beta III-tubulin expression in taxane-resistant malignancies
Charles Dumontet et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Expression of Multidrug Resistance Proteins in Prostate Cancer Is Related With Cell Sensitivity to Chemotherapeutic Drugs
Catherine Sanchez et al.
PROSTATE (2009)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
Targeting DNA topoisomerase II in cancer chemotherapy
John L. Nitiss
NATURE REVIEWS CANCER (2009)
Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy
Richard D. Sowery et al.
BJU INTERNATIONAL (2008)
Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival
Erin R. Gardner et al.
BJU INTERNATIONAL (2008)
C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer
Tomasz M. Beer et al.
CANCER (2008)
Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth
R. Bruce Montgomery et al.
CANCER RESEARCH (2008)
ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel
Tristan M. Sissung et al.
CLINICAL CANCER RESEARCH (2008)
Prospective Randomized Study Comparing Docetaxel, Estramustine, and Prednisone With Docetaxel and Prednisone in Metastatic Hormone-Refractory Prostate Cancer
Jean-Pascal Machiels et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study
Dominik R. Berthold et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
Gerhardt Attard et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents?
Pascal Seve et al.
LANCET ONCOLOGY (2008)
Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer
Lye Lin Ho et al.
PROSTATE (2008)
The 44-kDa pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells
Yingqiu Xie et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients - Randomized phase 2 study of ixabepilone or mitoxantrone and prednisone
Jonathan E. Rosenberg et al.
CANCER (2007)
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer:: a randomised, multicentre, placebo-controlled phase II study
Sten Nilsson et al.
LANCET ONCOLOGY (2007)
Paclitaxel and docetaxel resistance: Molecular mechanisms and development of new generation taxanes
Elena Galletti et al.
CHEMMEDCHEM (2007)
Androgen induces expression of the multidrug resistance protein gene MRP4 in prostate cancer cells
C. Cai et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2007)
Inflammation in prostate carcinogenesis
Angelo M. De Marzo et al.
NATURE REVIEWS CANCER (2007)
Interleukin 6, a nuclear factor-κB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-κB inhibition by PS-1145 enhances docetaxel antitumor activity
Josep Domingo-Domenech et al.
CLINICAL CANCER RESEARCH (2006)
Hormonal regulation of renal multlidrug resistance-associated proteins 3 and 4 (Mrp3 and Mrp4) in mice
JM Maher et al.
BIOCHEMICAL PHARMACOLOGY (2006)
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer
M Stanbrough et al.
CANCER RESEARCH (2006)
Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR)
JJ Lee et al.
SEMINARS IN ONCOLOGY (2005)
Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis
HI Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Human multidrug resistance associated protein 4 confers resistance to camptothecins
Q Tian et al.
PHARMACEUTICAL RESEARCH (2005)
Do β-tubulin mutations have a role in resistance to chemotherapy?
HK Berrieman et al.
LANCET ONCOLOGY (2004)
Mrp4 confers resistance to topotecan and protects the brain from chemotherapy
M Leggas et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma - Results of a meta-analysis
GM Lubiniecki et al.
CANCER (2004)
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance
J Holzbeierlein et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model
T Zellweger et al.
BJU INTERNATIONAL (2003)
Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer
W Berry et al.
JOURNAL OF UROLOGY (2002)
Expression of multidrug resistance related proteins and proliferative activity is increased in advanced clinical prostate cancer
JP Van Brussel et al.
JOURNAL OF UROLOGY (2001)
Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells
K Lee et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Expression of the multidrug resistance gene in human prostate cancer
G Bhangal et al.
UROLOGIC ONCOLOGY (2000)
Demonstration of MDR1 P-glycoprotein isoform expression in benign and malignant human prostate cells by isoform-specific monoclonal antibodies
K Kawai et al.
CANCER LETTERS (2000)
MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines
J Zalcberg et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2000)
Share Paper
